Veozah vs Paroxetine for Hot Flashes: Which Should You Ask About First?
Independent editorial research — educational only, not medical advice, and not a substitute for your own clinician. Not medically reviewed.
The 45-second answer
If you’re weighing Veozah vs paroxetinefor menopause hot flashes, the honest bottom line before you scroll: neither one is “better” for everyone. The right choice turns on one question most pages bury — are you taking tamoxifen? If you are, paroxetine is usually the wrong pick, because it can reduce how well tamoxifen protects you. If costis your wall, low-dose paroxetine is far cheaper. If you want a medicine designed specifically around hot-flash biology, Veozah was built for that — but it comes with a liver warning and blood tests.
Veozah (fezolinetant) is a non-hormonal pill built specifically for hot flashes and carries a liver-injury warning requiring scheduled blood tests. Paroxetine (as low-dose Brisdelle) is a cheaper, well-established option with no lab schedule, but it’s an antidepressant with its own warnings and a serious tamoxifen interaction. Your history decides which one to ask about first.
Best for / not for you
Veozah may fit you better if you:
- ✓Want a non-hormonal option designed around hot-flash biology, not a repurposed antidepressant
- ✓Are taking tamoxifen or another drug that makes paroxetine risky
- ✓Want to avoid antidepressant-type side effects
- ✓Can get liver blood tests before you start and on schedule after
- ✓Have commercial insurance or qualify for the manufacturer savings card
Paroxetine (Brisdelle) may fit you better if you:
- ✓Are hitting a cost or insurance wall — it’s dramatically cheaper
- ✓Would rather skip routine blood-test monitoring
- ✓Are not taking tamoxifen, and don’t have a history of bad reactions to SSRIs
- ✓Need a lower-cost first step your insurer will actually cover
Neither may be your right starting point if you:
- →Have liver disease, complex kidney disease, or a complicated medication list
- →Have symptoms that might not be menopause at all
- →Are actively in breast-cancer treatment and haven’t looped in your oncologist
- →Need a full risk review before starting any prescription
Veozah vs paroxetine: the at-a-glance comparison
Last verified July 2026. Prices move — always confirm your exact price and savings terms at checkout.
| Decision factor | Veozah (fezolinetant) | Paroxetine / Brisdelle (7.5 mg) |
|---|---|---|
| What it is | NK3 receptor blocker — calms the brain’s heat center directly | Low-dose SSRI (a type of antidepressant) |
| FDA-approved for hot flashes? | Yes — May 2023 | Yes — June 2013 (the first non-hormonal one) |
| Taking tamoxifen? | ✅ No CYP2D6 or tamoxifen interaction | ⚠️ Generally avoid — can reduce tamoxifen’s effect |
| Blood-test monitoring | ⚠️ Yes — liver panel at baseline, months 1, 2, 3, 6, 9 | ✅ None required |
| Boxed warning | Rare but serious liver injury (added Dec 2024) | Suicidal thoughts/behaviors (antidepressant-class) |
| Cash price / month | About $550–$770 (brand only, no generic) | Generic often $50–$70; brand Brisdelle much higher |
| Best savings path | Savings card: as low as $0 first month, ~$30 refills (commercial insurance only) | Low generic copay or discount card |
| How fast it works | Meaningful drop by ~4 weeks | Many women notice a difference within 1–2 weeks |
| Effect on weight / sex drive | Not an SSRI — no weight or libido effect reported | No change seen in trials (SSRI class caution still applies) |
| Also treats mood? | No | No — not approved for mood or anxiety at this dose |
| Main drawback | Cost + liver monitoring | SSRI class + tamoxifen conflict |
Read the whole table before you decide. The two rows people skip — tamoxifen and monitoring— are usually the ones that make the choice for you.
The HRT Indexis the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated.
The right non-hormonal option depends on your symptoms, your medication history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Use The HRT Index’s Find My HRT Path toolto match your situation to the right provider — and to flag when online care isn’t your right first step.
Still not sure which one fits? Take Find My HRT Path →Find My HRT Path asks health-related questions — please review our privacy policy before you share personal details.
So which should you ask about first? Start with three questions
Most of the Veozah-vs-paroxetine decision comes down to three things — your cancer history, your budget, and your tolerance for blood tests. Answer these three, and the choice usually gets obvious.
Question 1 — Are you taking tamoxifen, or might you?
If yes, most menopause specialists steer away from paroxetine and toward Veozah or a different non-hormonal option. This is the single biggest fork in the road, and we cover exactly why below.
Question 2 — Is cost the thing standing in your way?
If money is the barrier, low-dose paroxetine is the cheaper first step, and it’s what many insurers will ask you to try before they’ll cover Veozah. Veozah can still be affordable withcommercial insurance and the savings card — but not with Medicare or Medicaid.
Question 3 — Can you realistically do blood tests on a schedule?
Veozah requires a liver blood panel before you start and several times in the first year. If that’s not doable — no reliable lab access, needle anxiety, or you just won’t keep up with it — paroxetine avoids that entirely.
What we actually verified for this comparison
We built this page from the FDA labels, the published clinical trials, and the current savings and pricing programs — and we’ve flagged what we couldn’t confirm so you can spot-check it yourself. We separate three kinds of facts: medical (from the FDA and medical societies), commercial (prices and savings), and our own editorial read of who each drug fits.
| What we checked | Where it came from | When |
|---|---|---|
| FDA approval, dosing, warnings, liver thresholds | DailyMed labels (Veozah label updated Feb 26, 2026; current Brisdelle label) + FDA safety communications | Checked July 2026 |
| Trial results (how much each cuts hot flashes) | Peer-reviewed SKYLIGHT trials (Veozah) and the FDA Brisdelle label (paroxetine) | 2022–2023 |
| Indirect efficacy comparison (no head-to-head trial) | Bayesian network meta-analysis, Menopause journal | January 2024 |
| Both are top-tier recommended options | The Menopause Society 2023 non-hormone position statement | 2023 |
| Current cash + savings pricing | Manufacturer savings program, GoodRx, SingleCare, Drugs.com | Checked July 2026 |
| Which non-hormonal drugs a provider prescribes | Provider’s own public treatment pages (categories) | Checked July 2026 |
What still needs your own live check before you rely on it:
- ›Your exact Veozah cash price at your pharmacy, in your ZIP code — prices vary by $100+ between pharmacies
- ›Your exact out-of-pocket cost under your specific insurance plan
- ›Whether your plan requires “step therapy” (trying paroxetine first)
- ›Whether a given online provider prescribes your specific drug in your state right now — confirm at intake
How are Veozah and paroxetine different?
Veozah is fezolinetant — it targets your brain’s thermostat
When your estrogen drops in menopause, a brain chemical called neurokinin Bgets overactive. That throws off the part of your brain that controls body temperature — basically your internal thermostat starts misfiring, and you get the sudden wave of heat, flushing, and sweat we call a hot flash.
Veozah (generic name: fezolinetant) blocks the NK3 receptor that neurokinin B uses. Turn down that signal, and the thermostat settles. It’s not estrogen. It doesn’t touch your hormones at all. That’s why it’s an option for women who can’t take hormones — including many breast-cancer survivors.
Paroxetine (Brisdelle) is a low-dose antidepressant repurposed for heat
Paroxetine is an SSRI — the same family as Paxil. Doctors noticed decades ago that these drugs also calm hot flashes, likely by nudging the same brain-temperature circuitry through serotonin.
Here’s the part that confuses people: Brisdelle is paroxetine, but at 7.5 mg— a much smaller dose than the 20–40 mg used for depression. At that low dose it’s approved onlyfor menopause hot flashes. So if a clinician suggests “low-dose paroxetine,” they’re not saying you’re depressed. They’re using an old drug at a new, gentle dose for a specific job.
Why the mechanism matters
| The mechanism | What it means for you |
|---|---|
| Veozah blocks the NK3 pathway | Avoids SSRI-type side effects and withdrawal — but adds liver monitoring |
| Paroxetine blocks the CYP2D6 enzyme | Familiar and cheap — but creates the tamoxifen problem |
| Neither is a hormone | Both are options if you can’t take estrogen — but neither treats vaginal or urinary menopause symptoms |
This is not a “newer is better” story. It’s a “which trade-off fits your body and your life” story.
Veozah vs Brisdelle: is that the same comparison?
Yes — “Veozah vs Brisdelle” is the same decision as “Veozah vs paroxetine.” Brisdelle is simply the brand name for paroxetine mesylate 7.5 mg, the FDA-approved paroxetine product made specifically for menopause hot flashes. Just don’t confuse it with Paxil, which is a different paroxetine product at higher, antidepressant doses. You can’t swap Paxil in for Brisdelle without a clinician.
Which one works better for hot flashes?
| Trial result | Veozah 45 mg | Paroxetine 7.5 mg (Brisdelle) |
|---|---|---|
| Studied in | SKYLIGHT 1 & 2 (over 1,000 women) | Two phase 3 trials (over 1,170 women) |
| Fewer hot flashes/day vs placebo, week 4 | About 2.1 to 2.6 fewer | Roughly 1 to 1.5 fewer |
| Fewer hot flashes/day vs placebo, week 12 | About 2.5 fewer | Modest, and not significant on every measure |
| Women with 50%+ fewer hot flashes | Majority responded | 48% vs 36% on placebo (at 24 weeks) |
| Staying power | Held through 52 weeks | Benefit persisted at 24 weeks |
| What this proves | A real, measurable reduction | A real, measurable reduction — for many, not all |
The one honest limitation: there’s no direct head-to-head trial
No study has ever put Veozah and paroxetine in the same trial and compared them directly.Anyone who tells you one flatly “wins” is guessing.
The best available comparison is indirect. A 2024 network meta-analysis in the journal Menopause pooled the separate trials and estimated that Veozah 45 mg reduced moderate-to-severe hot flashes by about 1.66 more per day than paroxetine 7.5 mg — a modest but real edge. That same analysis found Veozah’s hot-flash reduction was not statistically different from the 27 hormone-therapy regimens studied— a genuinely notable result for a non-hormonal drug (though “not statistically different in an indirect analysis” is not the same as proof that Veozah equals hormone therapy for every woman).
Bottom line on efficacy: Veozah likely has a modest edge on raw hot-flash reduction. But “modest edge in a study” doesn’t beat “the one my body tolerates and I can afford.” Which is why cost and safety usually decide this — not a decimal point in a trial.
Which is safer — Veozah or paroxetine?
Veozah’s liver warning and the monitoring schedule
⚠ FDA Boxed Warning — Veozah (December 2024)
In December 2024, the FDA added a boxed warning — its most serious kind — to Veozah for rare but serious liver injury. It came after a case where a woman developed liver problems about 40 days into treatment. Her symptoms and lab values returned to normal after she stopped.
In the main trials, liver-enzyme problems were uncommon and usually mild, temporary, and resolved on their own. But because the risk is serious when it happens, the label now requires a clear testing routine.
| Veozah liver-test schedule | Details |
|---|---|
| Before you start | Liver blood panel (ALT, AST, alkaline phosphatase, bilirubin). Won’t start if baseline enzymes or bilirubin are ≥2× normal upper limit. |
| Monthly, first 3 months | Liver blood test at months 1, 2, and 3. |
| Month 6 | Liver blood test. |
| Month 9 | Liver blood test. |
| Stop immediately if… | Liver enzymes climb above 5× normal limit, or 3× limit with rising bilirubin. Also stop if you notice new tiredness, nausea, yellowing of eyes/skin, dark urine, or pale stools. |
Veozah is also contraindicated if you have known cirrhosis, severe kidney disease or end-stage renal disease, or if you take certain drugs called CYP1A2 inhibitors (your prescriber or pharmacist will check your list).
Paroxetine’s warnings and side effects
Every antidepressant, including low-dose paroxetine, carries a boxed warning about suicidal thoughts and behaviors— but the important context: that risk was seen mainly in children, teens, and adults under 25. In the studies, it was not increased in women over 24, and it actually went down in adults 65 and older. Still, anyone starting it should know to report new or worsening mood changes.
The most common side effects at the 7.5 mg dose are mild: headache, fatigue, and nausea.
- ›Don’t stop it cold turkey. SSRIs can cause withdrawal-type symptoms — dizziness, “brain zaps,” irritability — if stopped suddenly. You taper off with your clinician’s help.
- ›The reassuring part: in the trials, this low dose showed no significant effect on weight or sex drive — the two things women most often dread with antidepressants. That said, paroxetine’s label still counsels that sexual side effects are possible.
- ›A few other label cautions apply to some women — a higher bleeding risk if you also take blood thinners or regular NSAIDs, low blood sodium (mostly in older adults), and caution if you have a history of mania or seizures.
The tamoxifen problem — read this if you’re a breast-cancer survivor
⚠ Critical interaction: paroxetine + tamoxifen
Paroxetine is a strong blocker of a liver enzyme called CYP2D6.That enzyme is exactly what your body uses to turn tamoxifen — a common breast-cancer medication — into its active, cancer-fighting form (called endoxifen). Block the enzyme, and you can lower how much active tamoxifen your body makes.
Major clinical sources agree, and paroxetine’s own labeling flags it: potent SSRIs like paroxetine should generally be avoided in women taking tamoxifen. Retrospective data presented to ASCO in 2009 found that combining tamoxifen with moderate-to-strong CYP2D6 blockers was linked to a 25% to 92% greater relative risk of breast-cancer recurrence, depending on how long the two overlapped.
What this means for your choice:If you’re on tamoxifen, Veozah has no such interaction. That makes Veozah (or a non-paroxetine antidepressant like venlafaxine or citalopram) the safer non-hormonal route for many survivors. Make this decision with your oncologist, not on your own.
Quick medication-screening table
Before you choose, run down this list. If any row is you, flag it at your consult.
| If this is you | Why it matters | Ask your clinician |
|---|---|---|
| On tamoxifen (or may start it) | Paroxetine can reduce tamoxifen’s effect | “Should I avoid paroxetine and consider Veozah?” |
| Liver disease or high liver labs | Veozah is contraindicated in cirrhosis / won’t be started if labs are already high | “Is Veozah safe for me, or should I skip it?” |
| Severe kidney disease | Veozah is contraindicated | “Does my kidney function rule out Veozah?” |
| Take blood thinners or regular NSAIDs | Paroxetine can raise bleeding risk | “Is an SSRI safe with my current meds?” |
| Bad past reaction to an SSRI | Paroxetine may repeat it | “Should we skip SSRIs and look at Veozah?” |
| History of mania or seizures | Paroxetine label caution | “Is a low-dose SSRI still appropriate for me?” |
| Can’t reliably do lab work | Veozah monitoring is a real commitment | “Is a no-lab option better for me?” |
Disclosure: the provider links below are affiliate links — if you use one, The HRT Index may earn a commission. It never changes our verification standard or what we report.
Midi Health — verified fit for this decision
Midi is available in all 50 states with insurance coverage, and it runs a dedicated cancer-survivorship program led by a breast-cancer menopause expert. Midi’s own care page lists its non-hormonal prescriptions for hot flashes as fezolinetant (Veozah), gabapentin, SSRIs, and SNRIs— so it covers both sides of this comparison and specifically cares for women who can’t take hormones. Whether a specific drug like paroxetine fits you is confirmed during your intake.
See if Midi is available in your state →Straight talk:Midi is a membership-based visit — not the absolute cheapest way to get a prescription. But because Veozah needs scheduled liver monitoring, and because there’s a real chance the first medication you try isn’t the one you stay on, an ongoing menopause-literate clinician who tracks your labs and adjusts your plan is worth more here than a cheaper one-and-done script.
How much does each one cost?
| Medication | Source (checked July 2026) | 30-day price shown | Insurance needed? |
|---|---|---|---|
| Veozah (brand, 45 mg) | Drugs.com | ~$578 | No (cash) |
| Veozah (brand, 45 mg) | SingleCare | ~$772 retail / ~$474 with discount card | No (cash) |
| Veozah (brand, 45 mg) | GoodRx | ~$550–$700 (varies by pharmacy) | No (cash) |
| Veozah (brand, 45 mg) | Astellas Savings Card | $0 first month, ~$30 per refill | Yes — commercial insurance only |
| Paroxetine mesylate (generic, 7.5 mg) | SingleCare / GoodRx / Drugs.com | ~$51–$69 | No (cash) |
Your pharmacy and your plan price can differ. Confirm before you fill.
Veozah cost and the savings-card reality
- ›The Veozah Savings Card can bring eligible patients to as little as $0 for the first month and about $30 per refill. There’s an annual assistance cap of up to $4,000 per calendar year, and if a commercial claim isn’t approved, assistance may be limited to $1,250 for two fills.
- ›The catch: the savings card is for commercial (private) insurance only. It does not work with Medicare, Medicaid, TRICARE, or other government plans.
- ›Paying cash with no insurance? A GoodRx or SingleCare coupon typically lands in the $474–$700 range — still pricey, but better than sticker.
Paroxetine cost reality
Generic paroxetine mesylate 7.5 mg commonly runs about $51 to $69 for 30 capsules with a discount card. One important note: Brisdelle is the 7.5 mg hot-flash product.Standard generic paroxetine (10 mg, 20 mg) is even cheaper but is the antidepressant dose — don’t compare those prices as if they’re the same thing.
The hidden cost most pages skip: Veozah’s labs
When you compare prices, remember Veozah’s monitoring adds real-world cost. You’ll need a baseline liver panel plus five follow-up draws in the first year. Depending on your insurance, that’s extra visits and lab fees paroxetine simply doesn’t have. It doesn’t make Veozah a bad deal — but it’s part of the true cost.
What if insurance requires paroxetine before Veozah?
Many plans use “step therapy” — they’ll ask you to try the cheaper drug first before they’ll cover Veozah. That’s a coverage rule, not a medical verdict. If paroxetine isn’t right for you, your clinician can often submit a prior authorization to skip the step. Walk in ready to ask:
- ›What exactly counts as “failing” paroxetine, and how long do I have to try it?
- ›Does my tamoxifen use (or another CYP2D6 interaction) qualify me for an exception?
- ›Does a past bad reaction to SSRIs count?
- ›Can we document that I can complete Veozah’s liver monitoring?
- ›Will you submit the prior authorization and, if it’s denied, an appeal?
Can you take Veozah and paroxetine together?
Don’t combine Veozah and paroxetine unless the same clinician has reviewed your full medication list and specifically prescribed that plan. They’re two different approaches to the same problem, and stacking prescriptions adds interaction and side-effect complexity without a clear payoff.
If your first choice doesn’t deliver enough relief, the usual next step isn’t “add the other one” — it’s “try the other one instead,” under your clinician’s guidance.
Good questions to bring to that conversation:
- ›“Which one would you try first for my risk profile?”
- ›“How long until we know if it’s working?”
- ›“What side effect means I should stop and call you?”
- ›“If this one fails, what’s the backup?”
Who should ask about Veozah first — and who should ask about paroxetine?
| Your situation | More likely first question |
|---|---|
| Commercial insurance + can do labs + want to avoid SSRIs | Ask about Veozah |
| Cost is the wall / paying cash | Ask about paroxetine (the cheaper first step) |
| Taking tamoxifen | Ask about Veozah or a non-paroxetine option — with your oncologist |
| Liver disease or high liver labs | Ask about paroxetine (Veozah may be unsafe) |
| Can’t or won’t do routine blood tests | Ask about paroxetine (no monitoring) |
| Bad past reaction to SSRIs | Ask about Veozah |
| Insurer requires step therapy | Try paroxetine first, or request an exception if it’s wrong for you |
| Not sure your symptoms are even menopause | Start with a clinician evaluation |
What if neither is right for you?
Hormone therapy — still the most effective if you’re a candidate
The Menopause Society states that hormone therapy remains the most effective treatment for hot flashes, and it’s generally considered for healthy women within about 10 years of their final period. If hormones were ruled out only by preference — not by a medical reason — it may be worth revisiting that conversation.
Lynkuet (elinzanetant) — the newest non-hormonal option
Lynkuet is a dual NK1/NK3 receptor blocker, FDA-approved in October 2025, for moderate-to-severe hot flashes. Its late-stage studies also suggested it may ease menopause-related sleep problems. It’s brand-only and priced in Veozah’s range, so it’s worth asking about especially if Veozah coverage gets denied.
Other non-hormonal choices to discuss
- ›Venlafaxine (Effexor) or citalopram/escitalopram — antidepressants that reduce hot flashes and, unlike paroxetine, are safer alongside tamoxifen
- ›Gabapentin — can help night sweats, but may cause drowsiness
- ›Oxybutynin — another non-hormonal option with trial support
- ›CBT and clinical hypnosis — non-drug approaches the Menopause Society actually recommends
Note: vaginal estrogen is not a hot-flash treatment. It’s for vaginal and urinary symptoms. If hot flashes are your main problem, you need a whole-body (systemic) option, not a local one.
What to ask your clinician before you choose
Bring this checklist. Screenshot it if you like.
- 1.Are my symptoms clearly menopause-related?
- 2.Am I a candidate for hormone therapy, or do I specifically need a non-hormonal option?
- 3.Do any of my medications interact with paroxetine?
- 4.Am I taking tamoxifen — or could I be in the future?
- 5.Do my liver or kidney results affect whether I can take Veozah?
- 6.Can I realistically keep up with Veozah’s liver testing?
- 7.What will each option cost me, with my plan?
- 8.What do we do if the first option doesn’t work?
- 9.What side effects should make me stop and call you?
What to bring with you:
Your full medication and supplement list, any cancer-treatment history, recent liver/kidney labs if you have them, a screenshot of your insurance formulary, and a rough symptom count (hot flashes per day, night sweats per week, how it’s hitting your sleep).
What women tell us they’re weighing
Common concerns shared across menopause forums and our audience — not as proof that any drug works or is safe, and not as anyone’s medical result. Shared to show you’re not alone in these worries.
“I’m nervous about taking an antidepressant just for hot flashes.”
“My insurance wants me to try the cheaper drug before it’ll cover Veozah.”
“Veozah sounds great, but what’s it actually going to cost me?”
“I’m desperate for sleep — but I don’t want to trade hot flashes for side effects.”
If you’re feeling any of these, you’re in good company. Naming the worry is the first step to resolving it — usually with a five-minute question to the right clinician.
Frequently asked questions
- Is Veozah better than paroxetine?
- Veozah shows a modest edge on hot-flash reduction in indirect comparisons — roughly 1.66 fewer moderate-to-severe hot flashes per day than paroxetine in a 2024 network meta-analysis. But the two were never tested head-to-head, and “better in a study” doesn’t beat “the one your body tolerates and you can afford.” The right choice depends on your tamoxifen status, cost, and whether you can do liver monitoring.
- Is paroxetine the same as Brisdelle?
- Brisdelle is paroxetine at a low 7.5 mg dose, approved specifically for moderate-to-severe menopause hot flashes. Its label states it is not approved for depression, anxiety, or any psychiatric condition at that dose. So “low-dose paroxetine” and “Brisdelle” refer to the same hot-flash product.
- Is Brisdelle the same as Paxil?
- They share the same active drug (paroxetine), but they’re different products at different doses for different uses. Paxil is the higher-dose antidepressant; Brisdelle is the low 7.5 mg dose for hot flashes. Never swap doses or products without a clinician.
- Is Veozah a hormone?
- No. Veozah (fezolinetant) is a neurokinin 3 receptor antagonist that acts on the brain’s temperature center — not a hormone — which is exactly why it’s an option for women who cannot take estrogen.
- Which is cheaper, Veozah or paroxetine?
- Paroxetine, by a wide margin. Generic low-dose paroxetine typically runs $51–$69 a month. Veozah is about $550–$770 in cash, dropping to as little as $0–$30 with the manufacturer savings card — but only for people with commercial (not government) insurance.
- Does Veozah cause liver damage?
- Veozah carries an FDA boxed warning for rare but serious liver injury, added in December 2024. The label requires liver blood tests before starting, monthly for the first three months, and again at months 6 and 9. It is contraindicated in people with cirrhosis.
- Does paroxetine interact with tamoxifen?
- Yes — this is a major caution. Paroxetine strongly inhibits the CYP2D6 enzyme that converts tamoxifen into its active form, so most experts advise against using them together. If you take tamoxifen, ask your oncologist about Veozah or a non-paroxetine antidepressant instead.
- Does low-dose paroxetine cause weight gain or sexual side effects?
- At the 7.5 mg hot-flash dose, the trials found no significant effect on weight or sex drive — a real advantage over full antidepressant doses. Paroxetine’s label still notes that sexual side effects are possible, so it’s a fair thing to ask your clinician about.
- How fast does each one work?
- Many women notice paroxetine working within 1–2 weeks. Veozah produces a meaningful drop by around week 4. Neither works overnight, and your clinician should screen you properly before prescribing either.
- Can you take Veozah and paroxetine together?
- Only if one clinician has reviewed your full medication list and specifically prescribed that combination. As a rule, you pick one, give it a fair trial, and switch if needed — you don’t stack them on your own.
- What if my insurance makes me try paroxetine before Veozah?
- That’s step therapy, and it’s common for pricey brand drugs. Ask how long the trial must last, what counts as “failure,” and whether your clinician can file a prior authorization if paroxetine is genuinely wrong for you — for example, if you’re on tamoxifen.
- What if neither option is right for me?
- Ask about hormone therapy if you’re a candidate, the newer drug Lynkuet (elinzanetant), other antidepressants like venlafaxine, or non-drug options like CBT and clinical hypnosis. What fits depends on whether your main issue is hot flashes, sleep, mood, or something else.
The bottom line
If you’re on tamoxifen, start the conversation about Veozah (or a non-paroxetine option) — not paroxetine. If cost is your wall, low-dose paroxetine is the cheaper, no-labs first step. If you want the most hot-flash-specific option and can handle the liver tests, Veozah is the more targeted drug and may work a bit harder. Both are FDA-approved. Both are legitimate. Neither is a decision to make alone — but you now know the exact questions that decide it.
Still not sure which hot-flash treatment is right for you? Take our free Find My HRT Path assessment — about 90 seconds. It turns everything on this page into your personal starting point, and it’ll tell you honestly if seeing someone in person should come first.
Take Find My HRT Path →Sources
Medical, regulatory, and pricing sources (13)
- DailyMed — VEOZAH (fezolinetant) prescribing information, label updated February 26, 2026 (boxed warning, contraindications, liver-test thresholds, adverse reactions, dosing).
- FDA — Drug Safety Communication: rare but serious liver injury with Veozah (fezolinetant), September 2024; boxed warning added December 2024.
- DailyMed — BRISDELLE (paroxetine) 7.5 mg prescribing information (indication, boxed warning, Week 4/12 and 24-week responder data, not indicated for psychiatric use).
- The Lancet — Fezolinetant for moderate-to-severe vasomotor symptoms (SKYLIGHT 1): a phase 3 randomised controlled study, 2023.
- Journal of Clinical Endocrinology & Metabolism — Efficacy and Safety of Fezolinetant (SKYLIGHT 2): a phase 3 RCT, 2023.
- Menopause (The Menopause Society journal) — Systematic review and Bayesian network meta-analysis comparing fezolinetant with hormone and non-hormone therapies for VMS, January 2024.
- The Menopause Society — 2023 Nonhormone Therapy Position Statement (both paroxetine 7.5 mg and fezolinetant 45 mg rated Level I; hormone therapy most effective for VMS).
- PMC — Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of VMS.
- Clinical literature on paroxetine, CYP2D6, and tamoxifen: retrospective data presented at ASCO (2009) reporting 25%–92% greater relative recurrence risk with CYP2D6 inhibitors; MGH Center for Women’s Mental Health; peer-reviewed reviews.
- Pricing references checked July 2026 — Drugs.com, SingleCare, GoodRx (Veozah and generic paroxetine mesylate 7.5 mg); Astellas VEOZAH Savings Card terms.
- Provider treatment scope — Midi Health public care pages (available in all 50 states; cancer survivorship program; non-hormonal prescriptions listed as fezolinetant/Veozah, gabapentin, SSRIs, SNRIs), checked July 2026.
- DailyMed — LYNKUET (elinzanetant) label; FDA approval October 2025.
- Mayo Clinic — Hot flashes: diagnosis and treatment.
The HRT Index is the independent decision resource for online menopause and HRT care. This page is editorial research — educational only, not medical advice, and not medically reviewed by a clinician. FDA-approved and compounded options are always labeled distinctly. Always consult a licensed clinician before starting, stopping, or combining any medication. Some provider links are affiliate links; The HRT Index may earn a commission if you use them; this never changes our verification standard or recommendations. Last verified: July 2026.
